PSI CRO has significant experience in clinical trials designed to test new therapies for prostate cancer and has been chosen to spearhead the effort for INHIBITOR’S SUBA Prostate Program titled the “PREDICT” Study (Prostate Response Evaluating Docetaxel-Itraconazole Combination Therapy). This clinical program is planned to be carried out across approximately 35 sites in six countries in North America, Western Europe and Eastern Europe.

With IND clearance by FDA and future adequate funding, PREDICT will be launched as a Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2b Clinical Study Evaluating the Efficacy and Safety of SUBA-Itraconazole Capsules in combination with Docetaxel and Prednisone in Patients with Metastatic Castrate-Resistant Prostate Cancer (mCRPC).


PSI CRO is a privately-owned, full-service clinical research organization (CRO) operating globally. PSI’s global reach supports clinical trials across multiple countries and continents and is known to be highly selective about the work that they pursue. With an exceptionally high repeat and referral business rate combined with minimal staff turnover, PSI is committed to being the best CRO in the world as measured by its customers and its employees. In both 2015 and 2017, PSI was ranked as a Top CRO by the CenterWatch Investigative Site Survey. In 2018 PSI received 4 CRO Leadership Awards and added a 5th award to its collection in 2019.